Plasma Exchange Combination of Immunosuppressive Regimens for Auto-immune Hepatitis

NCT02874586 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2020-11-10

No results posted yet for this study

Summary

An open-label,pilot study to evaluate the efficacy and safety of plasma exchange combination of immunosuppressive regimens, for the remission of autoimmune hepatitis (AIH).

Conditions

  • Hepatitis, Autoimmune

Interventions

OTHER

Plasma exchange combination of immunosuppressive regimens

Sponsors & Collaborators

  • Xiaoli Fan

    lead OTHER

Principal Investigators

  • Li Yang, MD · West China Hospital,Chengdu, Sichuan, China

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-12-31
Primary Completion
2021-04-30
Completion
2021-09-30

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02874586 on ClinicalTrials.gov